Shares of KalVista Pharmaceuticals (NASDAQ:KALV) are tanking today after the company terminated the Phase 2 trial of KVD824 for treating hereditary angioedema (HAE).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The termination was based on elevated liver enzyme (ALT/AST) in patients across all treatment groups of the study.
Separately, the company continues to recruit for the Phase 3 trial of sebetralstat for the treatment of HAE attacks. Data from the study is expected in H2 2023.
Is KALV Stock a Good Buy?
KALV stock has declined nearly 61.3% over the past month. Nonetheless, four unanimous Buy ratings point to a Strong Buy consensus rating for the stock alongside an average price target of $43.75.
This implies a massive 616.04% upside potential for the stock.
